TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC

KRAS(G12C) is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRAS(G12C) inhibitors, sotorasib and adagrasib, have been an enormous breakthrough for patients with KRAS(G12C) mutant NSCLC; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tammaccaro, Salvina Laura, Prigent, Philippe, Le Bail, Jean-Christophe, Dos-Santos, Odette, Dassencourt, Laurent, Eskandar, Myriam, Buzy, Armelle, Venier, Olivier, Guillemot, Jean-Claude, Veeranagouda, Yaligara, Didier, Michel, Spanakis, Emmanuel, Kanno, Tokuwa, Cesaroni, Matteo, Mathieu, Stephane, Canard, Luc, Casse, Alhassan, Windenberger, Fanny, Calvet, Loreley, Noblet, Laurence, Sidhu, Sukhvinder, Debussche, Laurent, Moll, Jurgen, Valtingojer, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142471/
https://www.ncbi.nlm.nih.gov/pubmed/37111311
http://dx.doi.org/10.3390/ph16040553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142471/
https://www.ncbi.nlm.nih.gov/pubmed/37111311
http://dx.doi.org/10.3390/ph16040553

Ejemplares similares